CLINICAL TRIALS PROFILE FOR HEMANGEOL
✉ Email this page to a colleague
All Clinical Trials for HEMANGEOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01222091 ↗ | Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids | Completed | Stanford University | Phase 2 | 2009-02-01 | This research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil). Beta blockers inhibit the sympathetic (fight or flight) response and are often used to treat angina and high blood pressure. In a previous study in human volunteers, the investigators demonstrated an increased sensitivity to pain after a 60-minute infusion of the opioid remifentanil. The goal of this study is to identify a possible inhibitor of this phenomenon. |
| NCT02595996 ↗ | Propranolol Dose Escalation in Lymphedema in Patients | Terminated | Columbia University | Phase 2 | 2017-06-07 | This is a study to investigate the safety and efficacy of propranolol in the treatment of patients with primary lymphedema. The primary goal is to assess patient tolerability of increasing doses of propranolol. The secondary goal is to assess lymphedema symptoms and signs in response to propranolol treatment. |
| NCT02871349 ↗ | Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response | Completed | United States Department of Defense | Early Phase 1 | 2016-08-01 | The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism. |
| NCT02871349 ↗ | Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response | Completed | University of Missouri-Columbia | Early Phase 1 | 2016-08-01 | The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism. |
| NCT04741698 ↗ | Propranolol for Protracted Labor | Recruiting | Christiana Care Health Services | Phase 1 | 2021-07-27 | Induction of labor is one of the most common procedures performed on labor and delivery. In the United States, more than 20 percent of pregnant women undergo an induction of labor [1]. There is data from small, randomized studies that demonstrates the effectiveness of propranolol, a non-selective beta-blocker, for labor augmentation. This literature suggests a decrease in the amount of time to delivery and a possible reduction in cesarean section rates when propranolol is used in conjunction with oxytocin for induction of labor compared to oxytocin alone [2-8]. Alpha- and beta-adrenergic receptors have been identified in the human myometrium. Propranolol has been shown in studies to enhance uterine contractions and may be a useful tool in this population of women. Therefore, the purpose of this study is to assess whether the administration of propranolol at time of labor dystocia reduces time to delivery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HEMANGEOL
Condition Name
Clinical Trial Locations for HEMANGEOL
Trials by Country
Clinical Trial Progress for HEMANGEOL
Clinical Trial Phase
Clinical Trial Sponsors for HEMANGEOL
Sponsor Name
